ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal

ישראל - עברית - Ministry of Health

bioavenir ltd - pravastatin sodium 40 mg - tablets - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

ישראל - עברית - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.